Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.59 |
| ▸ | BTK | Q06187 | 7/20 | 0.59 |
| ▸ | JAK3 | P52333 | 14/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CCND3 | P30281 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 1/20 | 0.49 |
| ▸ | SKP1 | P63208 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21946318 | 1.00 | LCK (0.59) | LCKBTKJAK3EGFRSYK | |
| SCHEMBL21855164 | 1.00 | LCK (0.59) | LCKBTKJAK3EGFRSYK | |
| SCHEMBL31039906 | 1.00 | LCK (0.59) | LCKBTKJAK3EGFRSYK | |
| SCHEMBL21946907 | 0.91 | LCK (0.54) | LCKBTKJAK3EGFR | |
| SCHEMBL21946911 | 0.91 | LCK (0.54) | LCKBTKJAK3EGFRSYK | |
| SCHEMBL28637618 | 0.91 | BTK (0.62) | LCKBTKJAK3EGFRSYK | |
| SCHEMBL21946753 | 0.90 | CKS1B (0.48) | LCKBTKJAK3EGFRSYK | |
| SCHEMBL23484941 | 0.87 | JAK3 (0.71) | LCKBTKJAK3EGFR | |
| SCHEMBL21946347 | 0.87 | JAK3 (0.56) | LCKBTKJAK3EGFR | |
| SCHEMBL21946887 | 0.87 | JAK3 (0.64) | LCKBTKJAK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | LCK 125/4885BTK 3/4885JAK3 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.